These findings support previous results from our group evaluating the activity of the unconjugated humanized anti‐Trop‐2 monoclonal antibody hRS7 in ovarian cancer (Bignotti et al., 2012; Trerotola et al., 2013; Varughese et al., 2011a). Here, TACSTD2 is linked to ovarian carcinoma.